Comprehensive Stock Comparison
Compare XOMA Corporation (XOMAP) vs Eli Lilly and Company (LLY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMAP | 498.7% revenue growth vs LLY's 32.0% |
| Value |  LLY | Lower P/E (29.4x vs 38.7x) |
| Quality / Margins | XOMAP | 46.1% net margin vs LLY's 31.0% |
| Stability / Safety | XOMAP | Beta 0.13 vs LLY's 0.65, lower leverage |
| Dividends | XOMAP | 1.8% yield, vs LLY's 0.5% |
| Momentum (1Y) | XOMAP | +8.7% vs LLY's +8.6% |
| Efficiency (ROA) | LLY | 16.0% ROA vs XOMAP's 8.3%, ROIC 33.7% vs -37.6% |
Who Each Stock Is For
Income & stability
XOMAPDividend streak 0 yrs, beta 0.13, yield 1.8%
Growth exposure
XOMAPRev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
LLY13.2% 10Y total return vs XOMAP's 50.5%
Sleep-well-at-night portfolio
XOMAPLower volatility, beta 0.13, current ratio 5.15x
Defensive / Recession hedge
XOMAPBeta 0.13, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases like diabetes, cancer, and autoimmune disorders. It generates revenue primarily from drug sales — with diabetes treatments like Trulicity and Mounjaro contributing over 50% of revenue — and from oncology and immunology products. The company's competitive advantage lies in its deep research and development capabilities, particularly in diabetes and obesity treatments where it has established a strong patent-protected portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LLY 3XOMAP 1LLY4/6 metricsXOMAP3/4 metricsLLY6/9 metricsLLY4/6 metricsLLY leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). XOMAP leads in 1 (Valuation Metrics). 2 tied.
Financial Metrics (TTM)
LLY is the larger business by revenue, generating $59.4B annually — 1261.4x XOMAP's $47M. XOMAP is the more profitable business, keeping 46.1% of every revenue dollar as net income compared to LLY's 31.0%. On growth, LLY holds the edge at +53.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $47M | $59.4B |
| EBITDAEarnings before interest/tax | $13M | $28.6B |
| Net IncomeAfter-tax profit | $22M | $18.4B |
| Free Cash FlowCash after capex | $5M | $9.0B |
| Gross MarginGross profit ÷ Revenue | +93.6% | +83.0% |
| Operating MarginEBIT ÷ Revenue | -15.0% | +45.0% |
| Net MarginNet income ÷ Revenue | +46.1% | +31.0% |
| FCF MarginFCF ÷ Revenue | +11.4% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +53.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | +4.8% |
Valuation Metrics
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $317M | $898.2B |
| Enterprise ValueMkt cap + debt − cash | $335M | $928.6B |
| Trailing P/EPrice ÷ TTM EPS | -15.62x | 85.70x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.69x | 29.43x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.94x |
| EV / EBITDAEnterprise value multiple | — | 48.19x |
| Price / SalesMarket cap ÷ Revenue | 11.14x | 19.94x |
| Price / BookPrice ÷ Book value/share | 3.68x | 63.57x |
| Price / FCFMarket cap ÷ FCF | — | 2168.03x |
Profitability & Efficiency
LLY delivers a 77.2% return on equity — every $100 of shareholder capital generates $77 in annual profit, vs $20 for XOMAP. XOMAP carries lower financial leverage with a 1.46x debt-to-equity ratio, signaling a more conservative balance sheet compared to LLY's 2.36x. On the Piotroski fundamental quality scale (0–9), LLY scores 6/9 vs XOMAP's 4/9, reflecting solid financial health.
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | +20.1% | +77.2% |
| ROA (TTM)Return on assets | +8.3% | +16.0% |
| ROICReturn on invested capital | -37.6% | +33.7% |
| ROCEReturn on capital employed | -19.4% | +40.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 1.46x | 2.36x |
| Net DebtTotal debt minus cash | $18M | $30.4B |
| Cash & Equiv.Liquid assets | $102M | $3.3B |
| Total DebtShort + long-term debt | $119M | $33.6B |
| Interest CoverageEBIT ÷ Interest expense | 2.20x | 26.09x |
Total Returns (with DRIP)
A $10,000 investment in LLY five years ago would be worth $49,693 today (with dividends reinvested), compared to $14,590 for XOMAP. Over the past 12 months, XOMAP leads with a +8.7% total return vs LLY's +8.6%. The 3-year compound annual growth rate (CAGR) favors LLY at 47.3% vs XOMAP's 8.9% — a key indicator of consistent wealth creation.
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | -3.0% | -6.9% |
| 1-Year ReturnPast 12 months | +8.7% | +8.6% |
| 3-Year ReturnCumulative with dividends | +29.1% | +219.8% |
| 5-Year ReturnCumulative with dividends | +45.9% | +396.9% |
| 10-Year ReturnCumulative with dividends | +50.5% | +1316.4% |
| CAGR (3Y)Annualised 3-year return | +8.9% | +47.3% |
Risk & Volatility
XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than LLY's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.13x | 0.65x |
| 52-Week HighHighest price in past year | $30.00 | $1133.95 |
| 52-Week LowLowest price in past year | $24.96 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +85.9% | +88.5% |
| RSI (14)Momentum oscillator 0–100 | 38.3 | 44.8 |
| Avg Volume (50D)Average daily shares traded | 991 | 3.0M |
Analyst Outlook
Wall Street rates XOMAP as "Buy" and LLY as "Buy". For income investors, XOMAP offers the higher dividend yield at 1.81% vs LLY's 0.52%.
| Metric | XOMAPXOMA Corporation | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $1214.28 |
| # AnalystsCovering analysts | 9 | 44 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | +0.5% |
| Dividend StreakConsecutive years of raises | 0 | 10 |
| Dividend / ShareAnnual DPS | $0.47 | $5.18 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | 100 | 105.49 | +5.5% |
| Eli Lilly and Compa… (LLY) | 100 | 615.09 | +515.1% |
Eli Lilly and Compa… (LLY) returned +397% over 5 years vs XOMA Corporation (XOMAP)'s +46%. A $10,000 investment in LLY 5 years ago would be worth $49,693 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | $55M | $28M | -48.6% |
| Eli Lilly and Compa… (LLY) | $20.0B | $45.0B | +125.7% |
XOMA Corporation's revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR. Eli Lilly and Company's revenue grew from $20.0B (2015) to $45.0B (2024) — a 9.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -37.2% | -48.5% | -30.6% |
| Eli Lilly and Compa… (LLY) | 12.1% | 23.5% | +94.8% |
XOMA Corporation's net margin went from -37% (2015) to -49% (2024). Eli Lilly and Company's net margin went from 12% (2015) to 24% (2024).
Chart 4P/E Ratio History — 7 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Eli Lilly and Compa… (LLY) | 37 | 65.9 | +78.1% |
Eli Lilly and Company has traded in a 15x–101x P/E range over 7 years; current trailing P/E is ~86x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -1.82 | -1.65 | +9.3% |
| Eli Lilly and Compa… (LLY) | 2.18 | 11.71 | +437.2% |
XOMA Corporation's EPS grew from $-1.82 (2015) to $-1.65 (2024). Eli Lilly and Company's EPS grew from $2.18 (2015) to $11.71 (2024) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021). Eli Lilly and Company generated $414M FCF in 2024 (-92% vs 2021).
XOMAP vs LLY: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is XOMAP or LLY a better buy right now?
Eli Lilly and Company (LLY) offers the better valuation at 85.7x trailing P/E (29.4x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMAP or LLY?
On forward P/E, Eli Lilly and Company is actually cheaper at 29.4x.
03Which is the better long-term investment — XOMAP or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to +45.9% for XOMA Corporation (XOMAP). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus XOMAP's +50.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMAP or LLY?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus Eli Lilly and Company's 0.65β — meaning LLY is approximately 391% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, XOMA Corporation (XOMAP) carries a lower debt/equity ratio of 146% versus 2% for Eli Lilly and Company — giving it more financial flexibility in a downturn.
05Which has better profit margins — XOMAP or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus -48.5% for XOMA Corporation — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus -140.3% for XOMAP. At the gross margin level — before operating expenses — XOMAP leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XOMAP or LLY more undervalued right now?
On forward earnings alone, Eli Lilly and Company (LLY) trades at 29.4x forward P/E versus 38.7x for XOMA Corporation — 9.3x cheaper on a one-year earnings basis.
07Which pays a better dividend — XOMAP or LLY?
All stocks in this comparison pay dividends. XOMA Corporation (XOMAP) offers the highest yield at 1.8%, versus 0.5% for Eli Lilly and Company (LLY).
08Is XOMAP or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). Both have compounded well over 10 years (LLY: +1316%, XOMAP: +50.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XOMAP and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.